Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib + dexamethasone vs bortezomib + dexamethasone in relapsed multiple myeloma
jRCT2080222288Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Nov 2013
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of carfilzomib in multiple myeloma (MM) (2 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Progression-free survival (PFS). Started Nov 2013; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080222288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222288.